Skip to main content

CureVac N.V. (CVAC)

NASDAQ: CVAC · IEX Real-Time Price · USD
58.61
+0.57 (0.98%)
After-hours:Sep 24, 2021 7:30 PM EDT
58.04
0.19 (0.33%)
At close: Sep 24, 4:00 PM
Market Cap10.67B
Revenue (ttm)48.87M
Net Income (ttm)-129.12M
Shares Out186.83M
EPS (ttm)-1.14
PE Ration/a
Forward PE9.17
Dividendn/a
Ex-Dividend Daten/a
Volume342,378
Open56.65
Previous Close57.85
Day's Range56.55 - 58.27
52-Week Range43.30 - 151.80
Betan/a
AnalystsBuy
Price Target71.96 (+24.0%)
Est. Earnings DateNov 15, 2021

About CVAC

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenz...

IndustryBiotechnology
IPO DateAug 14, 2020
Employees455
Stock ExchangeNASDAQ
Ticker SymbolCVAC
Full Company Profile

Financial Performance

In 2020, CureVac's revenue was $48.87 million, an increase of 180.61% compared to the previous year's $17.42 million. Losses were -$129.12 million, 29.3% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CureVac stock is "Buy." The 12-month stock price forecast is 71.96, which is an increase of 23.98% from the latest price.

Price Target
$71.96
(23.98% upside)
Analyst Consensus: Buy

News

CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans

CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would terminate agreements with Celonic Group and Wac...

1 week ago - Benzinga

Why CureVac's Stock Is Down During Today's Session

CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pi...

1 week ago - Benzinga

Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now

The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.

1 month ago - The Motley Fool

Boehringer Ingelheim Scraps Lung Cancer Program With CureVac

CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated. CureVac and Boehringer had been working to...

1 month ago - Benzinga

Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today

Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. The post Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX...

Other symbols:BNTXNVAX
1 month ago - InvestorPlace

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

CureVac aims to become one of Europe's big suppliers.

2 months ago - The Motley Fool

Here's Why You Should Avoid CureVac Stock Like the Plague

Funds will not be safe if invested in this coronavirus stock.

2 months ago - The Motley Fool

Is CureVac a Bargain Bet on mRNA Vaccine Technology?

CureVac shares have slipped more than 20% on bad news.

2 months ago - The Motley Fool

Can CureVac Recover After Its Vaccine Setback?

Investors' dreams of a third strong mRNA vaccine may be over.

2 months ago - The Motley Fool

CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study

CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.

2 months ago - Zacks Investment Research

CureVac to 'plow forward' with Covid vaccine despite disappointing results

CureVac plans to continue work on its Covid-19 vaccine despite disappointing clinical trial results that showed the shot is just 48% effective.

2 months ago - CNBC

CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails Rivals

The German biotech company CureVac BV (NASDAQ: CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48% effectiveness at preventing the disease, wh...

2 months ago - Benzinga

Why Shares Of CureVac Are Trading Higher On Wednesday

CureVac (NASDAQ: CVAC) shares are trading higher after the company announced the appointment of Dr. Malte Greune as COO and the transition of Dr. Florian von der Mülbe to lead accelerated development of...

2 months ago - Benzinga

Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?

Things are looking bleak right now, but they might improve with enough time.

2 months ago - The Motley Fool

Why CureVac Shares Are Trading Lower Today

CureVac BV (NASDAQ:CVAC) shares are trading lower by 3.6% at $56 after the CDC said preliminary findings suggest the observed reports of heart inflammation after mRNA COVID-19 vaccines are greater than ...

3 months ago - Benzinga

Could CureVac Be a Millionaire-Maker Stock?

CureVac's first COVID vaccine candidate disappointed investors. But a second one looks promising.

3 months ago - The Motley Fool

How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.

Other symbols:AZNMRNAPFE
3 months ago - The Motley Fool

Morning Stock Movers: Raven, Torchlight, AMC, CureVac

Jun.21 -- Bloomberg's Kailey Leinz runs down the biggest moving stocks in today's pre-market trading.

Other symbols:AMCRAVN
3 months ago - Bloomberg Markets and Finance

Germany's BaFin looking into possible insider trading of CureVac shares

German financial watchdog BaFin is investigating possible insider trading of vaccine maker's CureVac shares, which fell after the biotech firm announced its COVID-19 vaccine proved only 47% effective, R...

3 months ago - Reuters

Why Is Everyone Talking About CureVac Stock?

This coronavirus vaccine developer just hit a massive stumbling block.

3 months ago - The Motley Fool

CVAC Stock Price Increases 14%: Why It Happened

CureVac BV (NASDAQ:CVAC) shares are trading higher by 14% at $66.16 as the stock rebounds after falling in recent sessions. The stock dipped after the company late Wednesday announced its COVID-19 vacci...

3 months ago - Benzinga

12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer

The news may reinforce Moderna's and Pfizer's vaccine-market dominance.

Other symbols:MRNAPFE
3 months ago - The Motley Fool

Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data

CureVac N.V.'s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Times reported on Thurs...

3 months ago - Benzinga

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

So what did the stock market do today? All eyes were on a World Bank decision and big moves in RIDE and CVAC stocks.

Other symbols:PFERIDE
3 months ago - InvestorPlace